An­oth­er re­pur­posed drug bites the dust in Covid-19 as An­gion bails on or­gan dam­age drug ef­fort

Since the ear­ly days of the pan­dem­ic, drug­mak­ers have tak­en a broad ap­proach to re­pur­pos­ing oth­er drugs in their pipeline against se­vere Covid-19 — a mis­sion that has met, with a cou­ple no­table ex­cep­tions, lit­tle tan­gi­ble suc­cess. Now, an­oth­er small biotech is throw­ing its hands up af­ter its or­gan dam­age drug turned up a dud in a se­vere Covid-19 study.

An­gion’s ANG-3777 missed its pri­ma­ry and sec­ondary end­points in a Phase II study in se­vere Covid-19 pa­tients with pneu­mo­nia at high risk of de­vel­op­ing acute res­pi­ra­to­ry dis­tress syn­drome, the biotech said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER